money.rediff.com
Cure8 news brief
Biocon Biologics Secures US Market Access for Yesintek
Access, cost, and policy
Ustekinumab
Biosimilars
IL-12/23 inhibitor
Regulatory Update
Adult patients
Patients On Biologics
Clinicians
Why This Matters
Formulary listings for Yesintek (ustekinumab biosimilar) could make an established IBD treatment more affordable and accessible for people with Crohn’s disease or ulcerative colitis. Wider payer coverage may affect which product pharmacies and insurers offer or prefer.
Who Should Pay Attention
Adults with Crohn’s disease or ulcerative colitis who are current or potential ustekinumab candidates, caregivers, clinicians who prescribe biologics, and patient advocates following drug access and cost issues.
Study Snapshot
Story typeBusiness news
Evidence typeRegulatory update
Source depthFull source text
What To Know
Yesintek is the company’s biosimilar version of ustekinumab and is being added to multiple US formularies, which may increase access and affordability for patients who are eligible for ustekinumab treatment. The report focuses on payer listings and formulary placement rather than clinical data or prescribing guidance.
Coverage details mentioned include commercial, Medicare, and managed Medicaid formulary additions with varying effective dates, and availability in the same presentations as Stelara (several prefilled syringe and vial options). The article quotes the company’s regulatory filing and executive comments about adoption and formulary validation.
This is market-access news: it does not provide new clinical trial results, safety information, or prescribing instructions. Patients should consult their clinicians or insurers about whether Yesintek will be covered for them and about any differences in product naming, substitution policies, or pharmacy processes.
Keep In Mind
This is a company report about payer formulary placements in the US; it does not present new clinical trial or safety data. Formulary coverage varies by plan and region—patients should check their specific insurer for coverage, prior authorization, or interchangeability policies.
The article cites a regulatory filing and lists payor effective dates but does not change clinical practice on its own.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationmoney.rediff.com
Indexed viaBing News
Source typeBusiness news
PublishedMay 4, 2025, 9:47 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
These are the drugs that lose their U.S. patents in 2025: most are in common use across the country by millions of people
Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...
Biocon Biologics unveils Yesintek biosimilar to Stelara in US
A new FDA‑approved ustekinumab biosimilar (YESINTEK) is now available in the US for Crohn’s disease and ulcerative colitis, which may increase treatment options and lower costs. Coverage and copay support at launch could...
Biocon Biologics launches Yesintek biosimilar to Stelara in US
A new FDA‑approved biosimilar to ustekinumab is now available in the U.S., which may increase treatment options and lower out‑of‑pocket costs for people with Crohn’s disease or ulcerative colitis. The article highlights...